Paxman will once again be exhibiting at the ESMO/EONS Annual Congress, the highly influential global oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
Here is what you can expect in Berlin.
ESMO 2025 will be a place where ground-breaking discoveries, cutting-edge treatments and a collaborative approach converge to shape the future of cancer care. Attendees will be able to learn from internationally renowned experts, engage in thought-provoking discussions and connect with fellow oncology professionals that are driving advancements in diagnosis, treatment and survivorship.
Chemotherapy-induced peripheral neuropathy (CIPN) – an unseen, debilitating, and lifelong condition – is currently an unmet clinical need. Commercial availability for a CIPN device is on the near horizon, but awareness of CIPN prevalence, its impact, and treatment implementation strategies remains a grey area for some healthcare professionals.
By attending this 45-minute session, you will walk away with a deeper understanding of CIPN prevalence and how it severely impacts patient quality of life. With examples of current clinical practice, you will gain the foundational knowledge healthcare institutions need to support and advocate for patients experiencing these side effects.
You can also expect insight into ongoing research in the field as well as an overview of the latest advancements in medical device development aimed at improving management outcomes in chemotherapy settings.
Mary Tanay RN, PhD
Dr Mary Tanay is a highly respected nurse researcher and clinician specialising in oncology, currently President-Elect of the UK Oncology Nursing Society. Originally trained in the Philippines, Mary qualified in nursing from the University of Santo Tomas before relocating to the UK, where she has been a Registered Nurse since 2000—working at leading trusts including the Royal Marsden and King’s College London.
Currently a Consultant Nurse at the Berkshire Cancer Centre, Mary plays a key role in integrating research into clinical practice, with a strong emphasis on improving quality of life for people undergoing chemotherapy. Her research has contributed to the growing body of evidence supporting person-centred, evidence-informed approaches to CIPN prevention and management. Mary has authored book chapters and published in peer-reviewed healthcare and nursing journals, as well as regularly speaking at national and international forums on CIPN, survivorship, and supportive care.
Elahe Salehi, DNO, ANP-BC
Dr Elahe Salehi is currently working as an oncology nurse practitioner for the department of breast oncology at the Dana-Farber Cancer Institute (DFCI). Her research focuses on improving the experience and safety of receiving cancer-directed therapies, with a focus on reducing toxicity and improving quality of life.
She designed and implemented scalp cooling best practice guidelines and policies at DFCI and is the principal investigator of DFHCC Trial 21-169, Assessing the Impact of Scalp Cooling in Patients with Metastatic Breast Cancer.
Her focus has been providing care to breast cancer patients from initial diagnosis through end-of-life care, including symptom management for chemotherapy-related side effects such as chemotherapy-induced peripheral neuropathy (CIPN). She has been actively involved in the evaluation and implementation of interventions aimed at minimising CIPN, helping patients navigate its impact on daily functioning and treatment adherence.
Dr Maryam Lustberg, MD, MPH, is Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, and Chief of Breast Medical Oncology at Yale Cancer Center. She is also a Professor of Medicine (Medical Oncology).
With a particular focus on improving the long-term outcomes for patients with breast cancer who have developed side effects associated with treatment, Maryam has been recognized for her patient-focused care with numerous awards. She has been rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of “Regional Top Doctors,” and “Exceptional Women in Medicine” for 2020.
Dr. Lustberg is a member of the ASCO Annual Meeting Education Committee, Patient and Survivor Care Education Committee, and Neuropathy Expert Guideline Panel. She is actively engaged in national patient advocacy organizations with a focus on improving shared decision making and increasing patient engagement in clinical trials. In addition, she serves as the President Elect and on the Board of Directors for the international organization Multinational Association of Supportive Care in Cancer (MASCC).
After 35 years at UCSF, H. Rugo has recently taken on the role of Director of the Women's Cancers Program and Division Chief of Breast Medical Oncology at the City of Hope Comprehensive Cancer Center, across their national network including academic and affiliate sites. Prior to this transition, she worked as a breast medical oncologist and Director of Breast Oncology and Clinical Trials Education at UCSF.
Several abstracts have been submitted for the event by our research partners across the world. It has been confirmed that more data from the Scalp Cooling Registry will be unveiled by Toni Brook, from Sheffield Hallam University in the UK, examining patient outcomes related to the number of scalp cooling sessions in various types of chemotherapy.
Session-Related Effects of Scalp Cooling: Analysis of the Dutch Scalp Cooling Registry T.S. Brook, C.J.G. Van Den Hurk
Head of International Sales
Regional Representative - Spain
Events Manager
Head of Brand and Marketing
